Corrigan Kelsey L, Paulus Rebecca, Klopp Ann H, Wenzel Lari B, Yeung Anamaria R, Thompson J Spencer, Doncals Desiree E, Kundapur Vijayananda, Wiggers Nancy H, Mohan Dasarahally S, Ghamande Sharad A, Westin Shannon N, Schnarr Kara L, Haas Michael L, Gaffney David K, Waggoner Steven E, Vanderwall Pamela J, Jastaniyah Noha T, Pugh Stephanie L, Kachnic Lisa A
University of Texas MD Anderson Cancer Center, Houston, TX.
NRG Oncology Statistics and Data Management Center, Philadelphia, PA.
JCO Oncol Adv. 2025 May 12;2(1):e2400088. doi: 10.1200/OA-24-00088. eCollection 2025.
NRG-RTOG 1203 reported that intensity-modulated radiation therapy (IMRT) reduced patient-reported GI toxicities in patients with cervical/endometrial cancer receiving postoperative RT, compared with 3-dimensional conformal radiation therapy (3DRT). We conducted a secondary analysis of patient-reported sexual function (PR-SF) among treatment groups to identify factors associated with sexual dysfunction.
Patients on NRG-RTOG 1203 were randomly assigned to 3DRT versus IMRT and completed Patient-Reported Outcomes (PRO)-Common Terminology Criteria for Adverse Events (CTCAE) and FACT-Cx surveys at baseline, week 5 of RT, and at 4-6 weeks, 1 year, and 3 years after RT. Patient responses to FACT-Cx sexual function questions were analyzed. The between-arm frequency and severity of responses and their comparison with PRO-CTCAE GI toxicity were tested using chi-square tests. A repeated-measures logistic regression model was used to determine the impact of clinical and treatment factors on PR-SF.
Two hundred thirty-six patients completed PR-SF questions; 125 (53%) received 3DRT and 111 (47%) IMRT. There were no significant differences in PR-SF between groups ( > .05). After RT, responses to "I am afraid to have sex" and "I am interested in sex" significantly improved over time ( = .007 and = .03, respectively). At 1 year after RT, women with interference from abdominal pain were more bothered by odor from the vagina versus women with no interference of abdominal pain (5% 0%, = .006). Additionally, at 1 year after RT, women with no severity of abdominal pain or no interference from abdominal pain liked their body appearance more versus women with at least some abdominal pain or some interference from abdominal pain (34% 13%, = .003 and 32% 6%, = .001, respectively).
PR-SF was similar between treatment groups. After RT, fear of sex declined and interest in sex improved over time. Women with GI toxicity after RT completion are at risk for worse sexual function.
NRG-RTOG 1203研究报告称,与三维适形放射治疗(3DRT)相比,调强放射治疗(IMRT)可降低接受术后放疗的宫颈癌/子宫内膜癌患者报告的胃肠道毒性。我们对各治疗组中患者报告的性功能(PR-SF)进行了二次分析,以确定与性功能障碍相关的因素。
NRG-RTOG 1203研究中的患者被随机分配至3DRT组或IMRT组,并在基线、放疗第5周、放疗后4 - 6周、1年和3年完成患者报告结局(PRO)-不良事件通用术语标准(CTCAE)和FACT-Cx调查。分析患者对FACT-Cx性功能问题的回答。使用卡方检验对组间反应的频率和严重程度及其与PRO-CTCAE胃肠道毒性的比较进行检验。采用重复测量逻辑回归模型来确定临床和治疗因素对PR-SF的影响。
236例患者完成了PR-SF问题;125例(53%)接受3DRT,111例(47%)接受IMRT。两组之间的PR-SF无显著差异(>0.05)。放疗后,对“我害怕进行性行为”和“我对性行为感兴趣”的回答随时间显著改善(分别为P = 0.007和P = 0.03)。放疗后1年,有腹痛干扰的女性比无腹痛干扰的女性更受阴道异味困扰(5%对0%,P = 0.006)。此外,放疗后1年,无腹痛严重程度或无腹痛干扰的女性比至少有一些腹痛或有腹痛干扰的女性对自己的身体外观更满意(分别为34%对13%,P = 0.003和32%对6%,P = 0.001)。
各治疗组之间的PR-SF相似。放疗后,对性行为的恐惧下降,对性行为的兴趣随时间改善。放疗结束后有胃肠道毒性的女性存在性功能更差的风险。